Journal Mobile Options
Table of Contents
Vol. 29, No. 1-2, 2007
Issue release date: November 2007
Neuroepidemiology 2007;29:39–43

Young-Onset Parkinson’s Disease: Hospital Utilization and Medical Comorbidity in a Nationwide Survey

Louis E.D. · Henchcliffe C. · Bateman B.T. · Schumacher C.
aGH Sergievsky Center, bDepartment of Neurology and cthe Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, and dDepartment of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: 10% of Parkinson’s disease (PD) patients have young-onset PD (YOPD). We compared YOPD patients to control patients in terms of hospital utilization and outcomes and medical comorbidities during hospitalization. Methods: The Nationwide Inpatient Sample (NIS) provides yearly data on hospital admissions and discharges from approximately 1,000 hospitals. NIS data sets (1998–2003) were used to identify persons aged 18–40 years, including 714 PD patients and 2,007 randomly selected control patients (1:3 matching). Results: Hospital length of stay (p < 0.001) and number of discharge diagnoses (p < 0.001) were higher in PD patients than controls. PD patients were more likely than controls to be discharged to a short-term hospital (odds ratio, OR, 2.23, 95% confidence interval, CI, 1.30–3.84, p = 0.004) or a skilled nursing facility (OR 4.14, 95% CI 3.06–5.61, p < 0.001); 20.4% required transfer to a short-term hospital or another facility. The most common discharge Diagnosis-Related Group code in PD patients was psychosis (23% of patients) whereas pneumonia and hip or pelvic fractures were not associated with PD. Conclusions: YOPD patients had greater healthcare utilization and hospital morbidity than controls. Upon discharge, 1 in 5 required transfer to a short-term hospital or another facility. Psychosis was the most common comorbidity whereas several comorbidities associated with older PD patients were not common.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH: Costs of drug treatment in Parkinson’s disease. Mov Disord 1998;13:249–254.
  2. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzsky RL: The health burdens of Parkinson’s disease. Mov Disord 199813:406–413.
  3. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M: The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844–849.
  4. Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD: Parkinsonism in Ontario: physician utilization. Can J Neurol Sci 2002;29:221–226.
  5. Pressley JC, Louis ED, Tang M-X, Cote L, Cohen PD, Glied S, Mayeux R: The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 2003;60:87–93.
  6. Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD: Burden of Parkinson’s disease: a population-based study. Mov Disord 2003;18:313–319.
  7. Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD: Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 2004;19:49–53.
  8. Cubo E, Alvarez E, Morant C, et al: Burden of disease related to Parkinson’s disease in Spain in the year 2000. Mov Disord 2005;20:1481–1487.
  9. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G: Burden of illness in Parkinson’s disease. Mov Disord 2005;20:1449–1454.
  10. Leibson CL, Maraganore DM, Bower JH, Ransom JE, O’Brien PC, Rocca WA: Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord 2006;21:446–455.
  11. Noyes K, Liu H, Li Y, Holloway R, Dick AW: Economic burden associated with Parkinson’s disease on elderly Medicare beneficiaries. Mov Disord 2006;21:362–372.
  12. Golbe LI: Young-onset Parkinson’s disease: a clinical review. Neurology 1991;41:168–173.
  13. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N: Young-onset Parkinson’s disease revisited – Clinical features, natural history, and mortality. Mov Disord 1998;13:885–894.
  14. Hervey SL, Purves HR, Guller U, Toth AP, Vail TP, Pietrobon R: Provider volume of total knee arthroplasties and patient outcomes in the HCUP-Nationwide Inpatient Sample. J Bone Joint Surg Am 2003;85:1775–1783.

    External Resources

  15. Dubinksy RM: No going home for hospitalized Huntington’s disease patients. Mov Disord 2005;10:1316–1322.
  16. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
  17. Goldstein LB, Samsa GP, Matchar DB, Horner RD: Charlson index of comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004;35:1941–1945.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50